Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33.
Cancer Facts & Figures 2020. Atlanta: American Cancer Society; 2021.Avalable at https://cancerstatisticscenter.cancer.org/#!/cancer-site/Pancreas. Accessed 31 Mar 2022
Ferrone CR, Pieretti-Vanmarcke R, Bloom JP, et al. Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery. 2012;152:S43–9.
Collisson EA, Sadanandam A, Olson P, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17:500–3.
CAS PubMed PubMed Central Article Google Scholar
Moffitt RA, Marayati R, Flate EL, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015;47:1168–78.
CAS PubMed PubMed Central Article Google Scholar
Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531:47–52.
CAS PubMed Article Google Scholar
Ciliberto D, Staropoli N, Chiellino S, et al. Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer. Pancreatology. 2016;16:249–58.
Egger G, Liang G, Aparicio A, et al. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004;429:457–63.
CAS PubMed Article Google Scholar
Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415–28.
CAS PubMed Article Google Scholar
Lomberk G, Blum Y, Nicolle R, et al. Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. Nat Commun. 2018;9:1978.
PubMed PubMed Central Article CAS Google Scholar
Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350–5.
CAS PubMed PubMed Central Article Google Scholar
Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409–13.
CAS PubMed PubMed Central Article Google Scholar
Yarchoan M, Hopkins A, Jaffee EM. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med. 2017;377:2500–1.
PubMed PubMed Central Article Google Scholar
Hu ZI, Shia J, Stadler ZK, et al. Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Clin Cancer Res. 2018;24:1326–36.
CAS PubMed PubMed Central Article Google Scholar
Chakravarthy A, Khan L, Bensler NP, et al. TGF-beta-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. Nat Commun. 2018;9:4692.
PubMed PubMed Central Article CAS Google Scholar
Ford K, Hanley CJ, Mellone M, et al. NOX4 Inhibition potentiates immunotherapy by overcoming cancer-associated fibroblast-mediated cd8 t-cell exclusion from tumors. Cancer Res. 2020;80:1846–60.
CAS PubMed PubMed Central Article Google Scholar
Kieffer Y, Hocine HR, Gentric G, et al. single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer. Cancer Discov. 2020;10:1330–51.
CAS PubMed Article Google Scholar
Topper MJ, Vaz M, Marrone KA, et al. The emerging role of epigenetic therapeutics in immuno-oncology. Nat Rev Clin Oncol. 2020;17:75–90.
Baylin SB, Jones PA. Epigenetic determinants of cancer. Cold Spring Harb Perspect Biol. 2016;8: a019505.
PubMed PubMed Central Article CAS Google Scholar
Okano M, Bell DW, Haber DA, et al. DNA methyltransferases dnmt3a and dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999;99:247–57.
CAS PubMed Article Google Scholar
Robert MF, Morin S, Beaulieu N, et al. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet. 2003;33:61–5.
CAS PubMed Article Google Scholar
Hou HA, Kuo YY, Liu CY, et al. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood. 2012;119:559–68.
CAS PubMed Article Google Scholar
Russler-Germain DA, Spencer DH, Young MA, et al. The R882H DNMT3A mutation associated with Aml dominantly inhibits wild-type Dnmt3a by blocking its ability to form active tetramers. Cancer Cell. 2014;25:442–54.
CAS PubMed PubMed Central Article Google Scholar
Robertson KD, Uzvolgyi E, Liang G, et al. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res. 1999;27:2291–8.
CAS PubMed PubMed Central Article Google Scholar
Li A, Omura N, Hong SM, et al. Pancreatic cancer DNMT1 expression and sensitivity to DNMT1 inhibitors. Cancer Biol Ther. 2010;9:321–9.
CAS PubMed Article Google Scholar
Sato N, Maitra A, Fukushima N, et al. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res. 2003;63:4158–66.
Rhee I, Bachman KE, Park BH, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature. 2002;416:552–6.
CAS PubMed Article Google Scholar
Da Costa EM, McInnes G, Beaudry A, et al. DNA Methylation-Targeted Drugs Cancer J. 2017;23:270–6.
Thakar M, Hu Y, Morreale M, et al. A novel epigenetic modulating agent sensitizes pancreatic cells to a chemotherapy agent. PLoS ONE. 2018;13: e0199130.
PubMed PubMed Central Article CAS Google Scholar
Von Hoff DD, Rasco DW, Heath EI, et al. Phase I study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors. Clin Cancer Res. 2018;24:4072–80.
Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324:930–5.
CAS PubMed PubMed Central Article Google Scholar
Fujikura K, Alruwaii ZI, Haffner MC, et al. Downregulation of 5-hydroxymethylcytosine is an early event in pancreatic tumorigenesis. J Pathol. 2021;254:279–88.
CAS PubMed Article Google Scholar
Wu J, Li H, Shi M, et al. TET1-mediated DNA hydroxymethylation activates inhibitors of the Wnt/beta-catenin signaling pathway to suppress EMT in pancreatic tumor cells. J Exp Clin Cancer Res. 2019;38:348.
PubMed PubMed Central Article CAS Google Scholar
Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19:17–30.
CAS PubMed PubMed Central Article Google Scholar
Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012;17:72–9.
CAS PubMed Article Google Scholar
Nunez FJ, Mendez FM, Kadiyala P, et al. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response. Sci Transl Med. 2019. https://doi.org/10.1126/scitranslmed.aaq1427.
Article PubMed PubMed Central Google Scholar
Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012;483:479–83.
CAS PubMed PubMed Central Article Google Scholar
Kadiyala P, Carney SV, Gauss JC, et al. Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice. J Clin Invest. 2021;131:e139542. https://doi.org/10.1172/JCI139542.
CAS Article PubMed Central Google Scholar
Roulois D, Loo Yau H, Singhania R, et al. DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. Cell. 2015;162:961–73.
CAS PubMed PubMed Central Article Google Scholar
Chiappinelli KB, Stri
留言 (0)